Hyloris Pharmaceuticals has reported a 44% increase in its revenues on the back of increased royalties and licensing income while doubling down on its R&D expenses and portfolio expansion in its 2023 annual results report.
The Belgian company’s revenue increased from EUR2.38m ($2.59m) to EUR4.4m, which Hyloris attributes the revenue growth to increased royalties and...








